{"nctId":"NCT00996658","briefTitle":"Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone","startDateStruct":{"date":"2009-10"},"conditions":["Diabetes Mellitus, Type 2"],"count":278,"armGroups":[{"label":"Linagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Linagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of diabetes mellitus prior to informed consent\n2. Patients treated with metformin and pioglitazone (therapy should be unchanged for 12 weeks)\n3. Glycosylated haemoglobin A1 \\>= 7.5% and \\<= 10%\n4. Age between 18 and less than 80\n5. \\- Body Mass index less or equal to 45\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycaemia during run in period\n2. Myocardial infarction, stroke or transient ischaemic accident within 3 months prior to informed consent\n3. Impaired hepatic function\n4. Gastric by pass surgery\n5. Treatment with roziglitazone, GLP 1 analogues, DPP-4 inhibitors or insulin within 3 months prior to informed consent\n6. Treatment with anti-obesity drugs\n7. Current treatment with systemic steroids at the time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent\n8. Premenopausal women who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control or do not plan to continue using this method during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.13"},{"groupId":"OG001","value":"-0.84","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.11"},{"groupId":"OG001","value":"-0.60","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.12"},{"groupId":"OG001","value":"-0.82","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.12"},{"groupId":"OG001","value":"-0.91","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Absolute Efficacy Response (HbA1c < 7%) After 24 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Absolute Efficacy Response (HbA1c < 6.5%) After 24 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Relative Efficacy Response (Reduction in HbA1c >= 0.5%) After 24 Weeks","description":"Glycosylated hemoglobin is reported as a percentage of the total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks","description":"Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"3.8"},{"groupId":"OG001","value":"-10.3","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) After 6 Weeks","description":"Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"5.4"},{"groupId":"OG001","value":"-3.3","spread":"4.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks","description":"Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"4.6"},{"groupId":"OG001","value":"-7.1","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) After 18 Weeks","description":"Adjusted mean change in fasting plasma glucose (FPG) from baseline at week 18","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.1"},{"groupId":"OG001","value":"-8.6","spread":"2.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":89},"commonTop":["Anaemia","Hyperglycaemia","Hypoglycaemia"]}}}